Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

EYETECH PHARMACEUTICALS

Home Clinical Trial Sponsors and OrganizationsEYETECH PHARMACEUTICALS

EYETECH PHARMACEUTICALS

42 Cummings Park, Woburn, Massachusetts, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

10

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

6

60.0%

Phase 4

3

30.0%

Not Applicable

1

10.0%

Trial Status Distribution

Completed

7

70.0%

Terminated

2

20.0%

Unknown

1

10.0%

Clinical Trials

Trials sponsored by this organization (10)

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Jun 20061,000 participants

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Apr 2006262 participants

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Mar 2005360 participants

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

May 200490 participants

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Mar 2004135 participants

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

Nov 2002125 participants

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

Page 1 of 2

Approvals

No approval data available

News

Life Biosciences Appoints Veteran Biotech Leader David Guyer to Board as Company Prepares for First Human Trials

- Life Biosciences has appointed industry veteran David Guyer, M.D., to its Board of Directors as the company prepares to initiate human trials for its lead program ER-100 in the first quarter of 2026. - Dr. Guyer brings over 30 years of drug development experience, including developing the first anti-VEGF drug for macular degeneration and overseeing the sale of EyeBio to Merck in July 2024. - The company's proprietary Partial Epigenetic Reprogramming platform utilizes three transcription factors to restore older cells to a younger state, targeting age-related diseases at the epigenetic level. - ER-100 is being developed for optic neuropathies including glaucoma and non-arteritic anterior ischemic optic neuropathy, representing a novel approach to treating age-related eye diseases.

On this page

Overview
Clinical Trials10
Approvals
News1

Back to Organizations